NEWAMSTERDAM PHARMA CO NV
NAMS · NASDAQ
Updated at 2026-10-13 14:27:43
- Today's High
- $21.34
- Today’s Low
- $20.81
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $21.28
- Previous Close
- $21.25
- Volume
- 812.29K
- Market Cap
- $2.54B
- P/E Ratio
- --
- EPS
- $-2.14
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- GOOIMEER 2-35, NAARDEN, NETHERLANDS, 1411 DC
- Country
- NL
- Listing Date
- 2022-11-23
- Fiscal Year End
- December
- Shares Outstanding
- 116.9M
- CIK
- 0001936258
- Website
- ir.newamsterdampharma.com
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to address critical unmet medical needs. With an advanced clinical development pipeline and a strategic commitment to reshaping treatment approaches, the company stands poised to significantly influence the healthcare landscape. Guided by a seasoned management team, NewAmsterdam offers a compelling investment opportunity for institutional investors aimed at facilitating transformative healthcare solutions that enhance patient outcomes while ensuring sustainable growth in the biopharmaceutical arena.
Financial Metrics
Revenue
2026-06-30
$3.7M
2026-03-31
$3.04M
2025-12-31
$32K
2025-09-30
$348K
Operating Expenses
2026-06-30
$68.56M
2026-03-31
$60.96M
2025-12-31
$65.95M
2025-09-30
$55.49M
Net Income
2026-06-30
-$64.13M
2026-03-31
-$48.44M
2025-12-31
-$74.92M
2025-09-30
-$72M
Net Profit Margin
2026-06-30
-1.73K%
2026-03-31
-1.59K%
2025-12-31
-234.13K%
2025-09-30
-20.69K%
Earnings Per Share
2026-06-30
$-0.52
2026-03-31
$-0.34
2025-12-31
$-0.63
2025-09-30
$-0.41
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$59.72M
2026-03-31
-$48.37M
2025-12-31
-$74.86M
2025-09-30
-$71.94M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $3.7M | $3.04M | $32K | $348K |
| Operating Expenses | $68.56M | $60.96M | $65.95M | $55.49M |
| Net Income | -$64.13M | -$48.44M | -$74.92M | -$72M |
| Net Profit Margin | -1.73K% | -1.59K% | -234.13K% | -20.69K% |
| Earnings Per Share | $-0.52 | $-0.34 | $-0.63 | $-0.41 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$59.72M | -$48.37M | -$74.86M | -$71.94M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.